Bone mineral density improvement in spondyloarthropathy after treatment with etanercept [5]

Annals of the Rheumatic Diseases

Volumn 62, Issue 10, 2003, Pages 1020-1021

  Marzo Ortega, H ^a   McGonagle, D ^a,b   Haugeberg, G ^a,c   Green, M J ^a   Stewart, S P ^d   Emery, P ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b Calderdale General Hospital   (United Kingdom)

^c DIAKONHJEMMET HOSPITAL   (Norway)

^d UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSORPTIOMETRY; ACCURACY; ADULT; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; IN VIVO STUDY; INFLAMMATION; LETTER; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; SPONDYLITIS; SPONDYLOARTHROPATHY; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

ADULT; BONE DENSITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141762482     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.10.1020     Document Type: Letter

References (5)

1. Gratacós J, Collado A, Pons F, Osaba M, Sanmartí R, Roque M, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis. Arthritis Rheum 1999;42:2319-24.
2. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondyloarthropathy. Arthritis Rheum 2001;44:2112-17.
3. Marzo-Ortega H, McGonagle, Haugeberg G, Astin P, Conaghan PG. Emery P. Significant loss of bone occurs early in inflammatory back pain in undifferentiated spondyloarthropathy [abstract]. Rheumatology (Oxford] 2002;41(suppl):S311.
4. Hofbauer I, Heufelder AE. The role of osteoprotegerin and receptor activation of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001;44:253-9.
5. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, et al. Expression of the osteoblast differentiation factor RUINX2 is inhibited by tumour necrosis factor alpha. J Biol Chem 2001;277:2695-701.